Comparing five advanced treatments for axial spondyloarthritis and psoriatic arthritis
Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor
This project will see how well bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor work for adults with axSpA or PsA who have just started one of these medicines, using medical records and patient surveys.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Adelphi Real World Industry-sponsored |
| Drugs / interventions | bimekizumab, risankizumab, guselkumab, adalimumab, upadacitinib |
| Locations | 1 site (Bath, Somerset) |
| Trial ID | NCT07166315 on ClinicalTrials.gov |
What this trial studies
This observational study will follow adults with axial spondyloarthritis or psoriatic arthritis who have begun treatment with one of five advanced therapies at participating NHS hospitals in the United Kingdom. Patients will complete surveys about symptoms, quality of life, and treatment experience during the study period. Investigators will also review participants' medical records retrospectively toward the end of follow-up to capture clinical outcomes, medication history, and healthcare use. The design is intended to provide real-world comparisons of effectiveness and patient-reported experience across these therapies.
Who should consider this trial
Good fit: Adults aged 18 or older with a clinical diagnosis of axSpA or PsA who started one of the listed advanced therapies within one month before enrollment and are not enrolled in another clinical trial.
Not a fit: Patients already taking the treatment for longer than one month before enrollment, those currently enrolled in another clinical trial, or those unable or unwilling to complete surveys are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could help patients and clinicians choose treatments that work better in everyday practice and better reflect patient experiences.
How similar studies have performed: Registries and observational studies have produced useful real-world effectiveness and safety data for TNF inhibitors and JAK inhibitors, while comparable real-world comparisons including newer agents like bimekizumab and some IL-23 inhibitors remain relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). * Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA. * Participant is aged 18 years or older at enrolment. Exclusion Criteria: -Participation in a clinical trial at enrolment.
Where this trial is running
Bath, Somerset
- Royal National Hospital for Rheumatic Diseases — Bath, Somerset, United Kingdom (Recruiting)
Study contacts
- Study coordinator: SpA Extend Team
- Email: arwspaextend@adelphigroup.com
- Phone: +441625 577 829
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.